{
  "docId": "019de070-fa64-77bc-8caf-8d60d9bebc40",
  "docSlug": "35e598705f15db6c29b5dc7bc3a9d06d",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 79 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 23,
  "pageCount": 79,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "key_messages",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes clinical trial data for NOV03 vs Saline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fa64-77bc-8caf-8d60d9bebc40/23",
  "deckHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40",
  "deckJsonHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40.json",
  "deckAnchorHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.55,
        "x": 0.42,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Market Opportunity: >16M Adults in the U.S. have some form of dry eye disease, with meibomian gland dysfunction as a known cause for a majority of these cases",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1946b468-0566-4f02-be7d-7511d83feb21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.42,
        "y": 0.15
      },
      "kind": "chart",
      "text": "NOV03: Phase 3 Topline Results",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be102103-8655-456c-91b4-4283801c758d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.73,
        "x": 0.25,
        "y": 0.86
      },
      "kind": "disclaimer",
      "text": "1. See Slide 1... 9. Intent-to-treat.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf4f4c92-9c90-42d6-b2e4-38dea051f99c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.38,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Readout of topline results of first of two Phase 3 trials for NOV03... Completed April 2021. Second Phase 3 trial ongoing... Expect to complete enrollment for Eyenovia Phase 3 trial... Expect to start Phase 3 trial for Risuteganib",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d01a8247-8eb2-4c5c-b8b6-0a46ceeb8c67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Near-term Catalysts: Bausch + Lomb",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35823499-4e87-4911-abe4-d40491ff97d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "title",
      "text": "R&D: Upcoming Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa0465fb-136f-41d5-b1b8-68999a26014a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 79,
      "from": 21,
      "beatId": "4729803e-b632-425a-8f97-04c24718552b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The company outlines its strategic plan and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 22,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "89154ab5-9a3d-4174-9970-e706cfacf4b3",
      "evidence": "The company discusses its strategic alternatives and timeline",
      "position": 1,
      "objective": "Why is now the right time for strategic alternatives?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}